 The European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has backed the approval of Amryt Pharma Plcs NASDAQ: AMYT Filsuvez in the European Union for partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa. 